PEAR

Pear Therapeutics, Inc. [PEAR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PEAR Stock Summary

In the News

PEAR Financial details

Company Rating
-
Market Cap
4.09M
Income
24.78M
Revenue
12.69M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
200
Optionable
No
Shortable
Yes
Earnings
09 Aug 2023
P/E
0.16
Forward P/E
-
PEG
-0.01
P/S
0.32
P/B
0.13
P/C
-
P/FCF
-0.03
Quick Ratio
1.34
Current Ratio
1.48
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.17
EPS next Y
-
EPS next Q
-
EPS this Y
-5.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-37.18%
EPS Q/Q
-184%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
26%
ROE
43%
ROC
-2.7%
Gross Margin
36%
Oper. Margin
-972%
Profit Margin
195%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.009-6.74
52W High
-
52W Low
-
RSI
-
Rel Volume
6.57
Avg Volume
10.09M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.519904
-
-
Volatility
0.01%, 0.01%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
MSFT
VFINX
GOOGL
DHR-PB
BRYN.DE
Same Sector
AVRO
TLRY.TO
300253.SZ
VCYT
VIVE
Check Those
BWAY
8092.HK
JAAA
000156.SZ
293780.KQ
Similar Market Cap
NBB.L
CAMP
SPRC
ARTL
ECT.AS

Company Profile

Healthcare Medical - Healthcare Information Services
  • Volume Average 10.09M
  • Market Capitalization 4.09M
  • Employee 200
  • CEO Mr. Christopher D. T. Guiffre J.D., M.B.A., MBA
  • Headquarters Boston,MA,US
  • IPO Date 2021-03-31
  • Website https://peartherapeutics.com

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.